You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
嘉和生物-B(06998.HK):GB492临床试验获国家药监局批准
格隆汇 05-20 08:52

格隆汇5月20日丨嘉和生物-B(06998.HK)公布,公司收到国家药品监督管理局关于GB492(IMSA101)干扰素基因刺激因子(S Timulator of interferongenes,STING)的临床试验批准。该I/IIa期临床试验会评估GB492单药以及与PD-(L)1单克隆抗体联合在晚期╱难治性恶性肿瘤患者中的安全性和有效性。

董事会亦欣然宣布,公司已委任德克萨斯大学西南医学中心分子生物学教授兼研究员陈志坚博士为公司的科学顾问委员会(Scientific Advisory Board)主席。陈博士拥有丰富的STING通路研究与探索经验。

GB492(IMSA101)干扰素基因刺激因子(S Timulator of interferongenes,STING)是癌细胞固有免疫感知的主要介导体,由集团于2020年6月向Immune Sensor Therapeutic获得独家许可协议。STING激动剂,作为一种免疫刺激疗法,将进一步增加患者对免疫检查点抑制剂的反应。多项研究显示,STING激动剂与其他免疫检查点抑制剂(ICI)联合使用可激活cGAS-STING信号通路,显着增强肿瘤免疫周期的疗效,将成为一种创新疗法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account